Alvotech's private placement completed with delivery of sdrs and shares to investors

Alvotech (nasdaq: alvo, alvo-sdb, the “company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement that was carried out on june 4, 2025, directed to swedish and international institutional investors. about 40 institutional investors participated in the placement. about 60% of the demand came from institutional investors based in sweden, norway or the uk, and about 30% from us-based funds. over 80% of the shares and swedish depositary receipts (sdrs) allocated in the placement, were sold to investors that were not previously shareholders in alvotech.
ALVO Ratings Summary
ALVO Quant Ranking